RxDoctor Payments Data

Asad Sawar, MD

Cardiovascular Disease · Tampa, FLNPI 1538168265

Payments from drug & device makers

$20,451in general payments, 2019–2025

Across 635 payments — averaging $32.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Cardiovascular Systems Inc.$2K
  • Penumbra, Inc.$2K
  • Novartis$825
  • Cvrx, Inc.$806
  • Medtronic$755
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$3,50019%
  • Travel & lodging$2952%
  • Food & beverage$14,18278%
  • Education$1981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca38$4,292
Cardiovascular Systems Inc.16$2,478
Penumbra, Inc.8$1,533
Novartis54$825
Cvrx, Inc.21$806
Medtronic(2 entities)22$755
Pfizer48$725
Biotronik Inc.35$662
Cook Medical LLC33$627
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)38$571
Sanofi-aventis U.S. LLC28$451
E.r. Squibb & Sons, L.L.C.34$402
Bayer18$386
Alnylam Pharmaceuticals Inc.11$369
Boehringer Ingelheim18$368
Inari Medical, Inc.2$363
Merck22$362
Boston Scientific18$361
Johnson & Johnson(2 entities)16$341
Abbott12$319
Impulse Dynamics (USA) Inc.4$293
Lundbeck LLC12$253
Shockwave Medical, Inc3$218
Abiomed3$166
Lexicon Pharmaceuticals, Inc.9$166
Actelion Pharmaceuticals US, Inc.8$157
Angiodynamics, Inc.4$157
Novo Nordisk8$155
Amarin Pharma, Inc.9$150
Amgen8$126
W. L. Gore & Associates, Inc.3$126
Philips North America LLC6$111
Stryker5$109
Bard Peripheral Vascular, Inc.1$100
Lantheus Medical Imaging, Inc.1$90
Esperion Therapeutics, Inc.6$85
Kestra Medical Technology Services, Inc.3$69
Vital Connect, Inc2$65
Regeneron Healthcare Solutions, Inc.3$60
EKOS Corporation3$55
Scpharmaceuticals Inc.2$55
Baxter Healthcare3$52
Chiesi USA, Inc.3$48
Astellas Pharma US Inc2$44
Acutus Medical, Inc.2$43
Tactile Systems Technology Inc2$41
Acist Medical Systems, Inc.2$41
Atricure, Inc.2$40
Kiniksa Pharmaceuticals, Ltd.3$40
Kiniksa Pharmaceuticals International, PLC2$35
Quidel Corporation1$34
Portola Pharmaceuticals, LLC2$31
CMS Imaging, Inc.1$31
Sanofi1$28
Elutia, Inc.4$25
Inspire Medical Systems, Inc.1$25
Kowa Pharmaceuticals America, Inc.2$22
Argon Medical Devices, Inc.1$22
United Therapeutics Corporation1$18
Infobionic, Inc1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,451 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,004,032
Medicare patients
1,736
Services billed
9,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,144$1,232,869
AdempasRiociguat25$339,678
XareltoRivaroxaban176$203,210
EntrestoSacubitril/Valsartan148$164,035
FarxigaDapagliflozin Propanediol135$117,010
MultaqDronedarone Hcl77$109,796
JardianceEmpagliflozin69$80,974
Repatha SureclickEvolocumab81$78,973
Repatha SyringeEvolocumab20$20,163
Dofetilide75$16,695
VerquvoVericiguat17$15,268
Praluent PenAlirocumab11$15,252
MounjaroTirzepatide12$12,766
Metoprolol Succinate926$11,976
Clonidine94$11,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$725$1,232,8691,144 claims
BayerAdempas$386$339,67825 claims
Johnson & JohnsonXarelto$341$203,210176 claims
NovartisEntresto$825$164,035148 claims
AstraZenecaFarxiga$4,292$117,010135 claims
Sanofi-aventis U.S. LLCMultaq$451$109,79677 claims
Boehringer IngelheimJardiance$368$80,97469 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$85$19,09635 claims
MerckVerquvo$362$15,26817 claims
AmgenCorlanor$126$7,60113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →